{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-125507","form_type":"8-K","ticker":null,"cik":"0001622879","company_name":"Medicine Man Technologies, Inc.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.019825+00:00","generated_at":"2026-05-29T08:42:35.248740+00:00","sec_items":["4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Schwazze restates 2022-2023 financials; prior statements no longer reliable","bullets":["Audit committee determined restatement needed for FY 2022, 2023, and Q1-Q3 2023 interim periods due to accounting errors.","Corrections include reclassification of preferred shares, operating leases, purchase accounting, inventory, debt, goodwill impairment.","Prior auditor BF Borgers was suspended by SEC in May 2024; re-audit by Baker Tilly underway.","Company does not expect negative material impact on revenue, adjusted EBITDA, cash from operations.","Previously issued reports and earnings releases for Subject Periods should no longer be relied upon."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-125507","json":"https://secwatch.observer/filing/0001104659-24-125507.json","markdown":"https://secwatch.observer/filing/0001104659-24-125507.md","text":"https://secwatch.observer/filing/0001104659-24-125507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622879/000110465924125507/0001104659-24-125507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622879/000110465924125507/tm2430193d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:42:35.248740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fe957761f12e875dc4fb6119dbdbbf778edcfa3","claim":"Medicine Man Technologies, Inc. engaged Baker Tilly US, LLP as its auditor.","evidence_excerpt":"On April 5, 2024, the Audit Committee (the “Audit Committee”) of Medicine Man Technologies, Inc. (the “Company”) dismissed BF Borgers CPA, PC (“Borgers”) as the Company’s independent registered public accountant and subsequently appointed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s new independent registered public accountant.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622879/000110465924125507/0001104659-24-125507-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Baker Tilly US, LLP"}],"fact_type":"auditor_change"},{"claim_id":"3ca43dc600982582525a23bef56264eee4b1bbb6","claim":"Medicine Man Technologies, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"On November 29, 2024, the Audit Committee of the Company determined, following discussions with Baker Tilly and the Company’s management, that the Company’s previously issued audited consolidated financial statements for the two fiscal years ended December 31, 2022 and December 31, 2023, as filed on the 2023 Form 10-K audited by Borgers, and the Company’s unaudited condensed consolidated financial statements and the notes thereto as of and for the fiscal periods ended March 31, 2023, June 30, 2023, and September 30, 2023 included in the Company’s Quarterly Reports on Form 10-Q (collectively the “Subject Periods”) will be restated","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622879/000110465924125507/0001104659-24-125507-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"},{"claim_id":"44bec0fc689deead69a4d2af6f777128f19766f7","claim":"Medicine Man Technologies, Inc. dismissed BF Borgers CPA, PC as its auditor.","evidence_excerpt":"On April 5, 2024, the Audit Committee (the “Audit Committee”) of Medicine Man Technologies, Inc. (the “Company”) dismissed BF Borgers CPA, PC (“Borgers”) as the Company’s independent registered public accountant and subsequently appointed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s new independent registered public accountant.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622879/000110465924125507/0001104659-24-125507-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"BF Borgers CPA, PC"},{"label":"Successor","value":"Baker Tilly US, LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}